Seattle Children's Hospital

Running trials

• Not yet recruiting

  NANT 2021-02: Randomized MIBG With Vorinostat/Dinutuximab/Vorinostat + Dinutuximab

  NCT07261241· Phase 2· New Approaches to Neuroblastoma Therapy Consortium· Source

• Not yet recruiting

  COMparison Between Anakinra and Tocilizumab in NORSE - "COMBAT-NORSE"

  NCT07281027· Phase 3· Yale University· Source

• Not yet recruiting

  A Study of CLEC2A CAR T for Pediatric and Adult Patients With Relapsed or Refractory AML

  NCT07905027· Phase 1· Seattle Children's Hospital· Source

• Not yet recruiting

  IMPACT-Ready Study

  NCT07931690· Coalition for Aligning Science· Source

• Not yet recruiting

  Rethinking Early Airway Clearence Therapies

  NCT07696338· Nicole Hamblett· Source

• Recruiting

  Illuminate: A Clinical Study Evaluating CAR T Immune Cell Therapy (BCB-276) for Patients With Diffuse Intrinsic Pontine Glioma (DIPG).

  NCT07680439· Phase 2· BrainChild Bio, Inc· Source

• Recruiting

  A Tailored Medication Adherence-Promotion Intervention for Adolescents and Young Adults With Cancer

  NCT07223463· Children's Hospital Medical Center, Cincinnati· Source

• Recruiting

  A Study Comparing Higher Dose Chemotherapy Over a Shorter Amount of Time to Lower Dose Chemotherapy Plus Maintenance Over a Longer Amount of Time in Patients With Newly Diagnosed Intermediate-Risk Rhabdomyosarcoma (IR RMS)

  NCT07466316· Phase 3· Children's Oncology Group· Source

• Recruiting

  A Study to Find the Highest Dose of Cedazuridine and Decitabine Combination With Filgrastim as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With High-Risk Acute Myeloid Leukemia

  NCT07012044· Phase 1· National Cancer Institute (NCI)· Source

• Recruiting

  ASCEND: Safety and Tolerability of ION337 for the Treatment of Dravet Syndrome

  NCT07531745· Phase 1/2· Ionis Pharmaceuticals, Inc.· Source

• Recruiting

  Familial Inflammatory Bowel Disease Early Risk

  NCT07791862· Seattle Children's Hospital· Source

• Recruiting

  A Randomized Phase 1/2 Trial of Low Dose Anti-thymocyte Globulin (ATG) With Subsequent Adalimumab or Verapamil in New Onset Type 1 Diabetes

  NCT07061574· Phase 1/2· City of Hope Medical Center· Source

• Recruiting

  Starlight Cardiovascular Lifeline Ductus Arteriosus Stent IDE Study

  NCT07114718· Starlight Cardiovascular Inc· Source

• Recruiting

  Immunotherapy for Solid Tumor Malignancies in Pediatrics Using Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor T Cells

  NCT07148050· Phase 1· Seattle Children's Hospital· Source

• Active, not recruiting

  A Study to Find Out How EMPAgliflozin is Tolerated and if it Helps Children and Adolescents With Chronic KIDNEY Disease (EMPA-KIDNEY® Kids)

  NCT07107945· Phase 3· Boehringer Ingelheim· Source

• Recruiting

  A Study Evaluating the Real-World Experience of Givinostat in Patients With Duchenne Muscular Dystrophy

  NCT07127978· ITF Therapeutics LLC· Source

• Recruiting

  Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion

  NCT06333899· Early phase 1· Nationwide Children's Hospital· Source

• Recruiting

  ACT001 for the Treatment of Diffuse Intrinsic Pontine Gliomas and H3K27-altered High Grade Gliomas

  NCT06838676· Phase 2· Nationwide Children's Hospital· Source

• Recruiting

  Cognitive Aftereffects of Neurotoxicity in Children and Young Adults With Relapsed/Refractory Hematologic Malignancies Who Receive CAR T-cell Therapy

  NCT05237986· National Cancer Institute (NCI)· Source

• Active, not recruiting

  Testing the Addition of an Anti-Cancer Drug, AZD1390, During Radiation Therapy for Newly Diagnosed High Grade Glioma, Diffuse Midline Glioma, or Diffuse Intrinsic Pontine Glioma

  NCT06894979· Phase 1· Children's Oncology Group· Source

• Active, not recruiting

  A Study to Learn More About the Effects and Long-Term Safety of Omaveloxolone (BIIB141) in Children and Teens With Friedreich's Ataxia

  NCT06953583· Phase 3· Biogen· Source

• Recruiting

  Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

  NCT06317662· Phase 2· National Cancer Institute (NCI)· Source

• Recruiting

  TIDES 2.0: Prevalence and Longitudinal Course of Depression, Anxiety, and Behavior Problems in Children With Cystic Fibrosis Under 12 Years of Age

  NCT07048574· State University of New York at Buffalo· Source

• Recruiting

  A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)

  NCT06124157· Phase 2· National Cancer Institute (NCI)· Source

• Recruiting

  Restarting Triple Therapy With Robust Monitoring for Adverse Events (RETRIAL)

  NCT06683092· Boston Children's Hospital· Source

• Recruiting

  Tirzepatide in PWS, HO and GNSO

  NCT06901245· Phase 4· Grace Kim· Source

• Recruiting

  Resource Intervention to Support Equity (RISE) in High-Risk Neuroblastoma

  NCT06831552· Dana-Farber Cancer Institute· Source

• Recruiting

  Effects of High-Resistance Inspiratory Muscle Strength Training on Cardiorenal and Vascular Function in Youth and Young Adults With Type 2 Diabetes

  NCT06936670· Seattle Children's Hospital· Source

• Recruiting

  Multicenter Trial of ECMO in Children With Severe Cardiac Failure Using the Cardiohelp System

  NCT06080074· Phase 2· Stanford University· Source

• Recruiting

  A Study Using Risk Factors to Determine Treatment for Children With Favorable Histology Wilms Tumors (FHWT)

  NCT06401330· Phase 3· Children's Oncology Group· Source

• Recruiting

  Testing a Standardized Approach to Surgery and Chemotherapy for Type I Pleuropulmonary Blastoma or the Addition of an Anti-cancer Drug, Topotecan, to the Usual Treatment for Types II and III Pleuropulmonary Blastoma

  NCT06647953· Phase 3· Children's Oncology Group· Source

• Recruiting

  Ziftomenib in Combination With Chemotherapy for Children With Relapsed/Refractory Acute Leukemia

  NCT06376162· Phase 1· PedAL BCU, LLC· Source

• Enrolling by invitation

  Assessment of Worldwide Acute Kidney Injury Epidemiology in Neonates 2.0

  NCT06823115· Indiana University· Source

• Recruiting

  Triptorelin for the Prevention of Ovarian Damage in Adolescents and Young Adults With Cancer

  NCT06513962· Phase 3· Children's Oncology Group· Source

• Recruiting

  Study of Olutasidenib and Temozolomide in HGG

  NCT06161974· Phase 2· Rigel Pharmaceuticals· Source

• Recruiting

  A Phase 2 Study of WU-CART-007, an Anti-CD7 Allogeneic CAR-T Cell Therapy in T-Cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma (T-RRex)

  NCT06514794· Phase 2· Allotera Therapeutics· Source

• Recruiting

  A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo

  NCT06548360· Phase 3· Incyte Corporation· Source

• Recruiting

  A Study of Dulaglutide (LY2189265) 3.0 mg and 4.5 mg in Pediatric Participants With Type 2 Diabetes Mellitus (AWARD-PEDS PLUS)

  NCT06739122· Phase 3· Eli Lilly and Company· Source

• Recruiting

  REACT-01: Reversing Autoimmunity Through Cell Therapy

  NCT06465147· Phase 1· Seattle Children's Hospital· Source

• Recruiting

  NANT 2021-01 Phase II STING (Sequential Temozolomide, Irinotecan, NK Cells and GD2 mAb) Trial

  NCT06450041· Phase 2· New Approaches to Neuroblastoma Therapy Consortium· Source

• Recruiting

  Safety, Tolerability and Efficacy Study of ARCT-032 in People With Cystic Fibrosis

  NCT06747858· Phase 2· Arcturus Therapeutics, Inc.· Source

• Recruiting

  Streamlined Treatment of Pulmonary Exacerbations in Pediatrics

  NCT06654752· University of Washington, the Collaborative Health Studies Coordinating Center· Source

• Active, not recruiting

  A Study to Learn About the Study Medicine Called Rimegepant in Adolescents With Frequent Migraine

  NCT06616194· Phase 3· Pfizer· Source

• Recruiting

  A Study of Lower Radiotherapy Dose to Treat Children With CNS Germinoma

  NCT06368817· Phase 2· Children's Oncology Group· Source

• Recruiting

  A Culturally-Tailored Mobile Health and Social Media Physical Activity Intervention for Improving Physical Activity in Hispanic or Latino/Latina Adolescent and Young Adult Childhood Cancer Survivors, Walking Juntos Study

  NCT06410209· Phase 2· Children's Oncology Group· Source

• Recruiting

  A Phase I/II Study of Trametinib and Azacitidine for Patients With Newly Diagnosed Juvenile Myelomonocytic Leukemia

  NCT05849662· Phase 1/2· Therapeutic Advances in Childhood Leukemia Consortium· Source

• Recruiting

  Registry Study to Observe Long-term Safety of Vamorolone (AGAMREE®) in Patients With Duchenne Muscular Dystrophy-SUMMIT

  NCT06564974· Catalyst Pharmaceuticals, Inc.· Source

• Recruiting

  A Research Study to Advance the CF Therapeutics Pipeline for People Without Modulators

  NCT06504589· Nicole Hamblett· Source

• Recruiting

  Transforming Care for Individuals With Childhood-onset Systemic Lupus Erythematosus

  NCT06232304· Michigan State University· Source

• Recruiting

  Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant

  NCT05843253· Phase 2· Nationwide Children's Hospital· Source

Showing 50 of 223.

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Childhood cancers63 recruiting
• Acute lymphoblastic leukaemia10 recruiting
• Cystic fibrosis8 recruiting
• Neuroblastoma8 recruiting
• Acute myeloid leukaemia7 recruiting
• Sarcoma7 recruiting
• Duchenne muscular dystrophy6 recruiting
• Chronic kidney disease4 recruiting
• Crohn's disease4 recruiting
• Down syndrome4 recruiting
• Epilepsy4 recruiting
• Glioblastoma4 recruiting
• High blood pressure4 recruiting
• Kidney cancer4 recruiting
• Type 2 diabetes4 recruiting
• Charcot-Marie-Tooth disease3 recruiting
• Congenital heart disease3 recruiting
• Hearing loss3 recruiting
• Lupus (SLE)3 recruiting
• Pulmonary arterial hypertension3 recruiting
• Ulcerative colitis3 recruiting
• Autism2 recruiting
• Heart failure2 recruiting
• Hodgkin lymphoma2 recruiting
• Migraine2 recruiting
• Obesity2 recruiting
• Ovarian cancer2 recruiting
• Thyroid cancer2 recruiting
• Type 1 diabetes2 recruiting
• Chronic lymphocytic leukaemia1 recruiting
• Chronic myeloid leukaemia1 recruiting
• CIDP (chronic inflammatory demyelinating polyneuropathy)1 recruiting
• Fabry disease1 recruiting
• Gaucher disease1 recruiting
• Hydrocephalus1 recruiting
• IgA nephropathy1 recruiting
• Irritable bowel syndrome1 recruiting
• Liver and biliary tract cancer1 recruiting
• Lung cancer1 recruiting
• Myelodysplastic syndromes1 recruiting
• Myeloproliferative neoplasms1 recruiting
• Neuroendocrine tumours1 recruiting
• Obstructive sleep apnoea1 recruiting
• Pompe disease1 recruiting
• Psoriasis1 recruiting
• Psoriatic arthritis1 recruiting
• Retinitis pigmentosa1 recruiting
• Rheumatoid arthritis1 recruiting
• Sjögren's disease1 recruiting
• Stroke1 recruiting
• Vitiligo1 recruiting

Closed trials

• Recruiting

  Selpercatinib Pre-RAI in Patients With RET Fusion Thyroid Cancer (RAISE)

  NCT06458036· Phase 2· Children's Hospital of Philadelphia· Source

• Completed

  A Study To Evaluate The Safety Of CMTX-101 In People With Cystic Fibrosis

  NCT06159725· Phase 1/2· Clarametyx Biosciences, Inc.· Source

• Completed

  Dynamic Quantification of Social-Visual Engagement in Autism Spectrum Disorder (ASD)

  NCT05806216· EarliTec Diagnostics, Inc· Source

• Terminated

  Effectiveness Trial of Mobile ESI for Toddlers With Autism Identified by Early Screening in Primary Care

  NCT05456139· Florida State University· Source

• Completed

  A Pilot Feasibility Trial of a Tailored Intervention to Improve Adherence in Adolescents and Young Adults With Cancer

  NCT05706610· Children's Hospital Medical Center, Cincinnati· Source

• Completed

  Observational Study Comparing Home to Office Spirometry

  NCT05285410· Chris Goss· Source

• Recruiting

  A Study to Learn More About How Safe the Study Treatment Finerenone is in Long-term Use When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker Over 18 Months of Use in Children and Young Adults From 1 to 18 Years of Age With Chronic Kidney Disease and Proteinuria

  NCT05457283· Phase 3· Bayer· Source

• Completed

  Vaccine Immune Recovery After Leukemia

  NCT05622682· Children's Hospital of Philadelphia· Source

• Completed

  Mono vs. Dual Therapy for Pediatric Pulmonary Arterial Hypertension

  NCT04039464· Phase 3· Johns Hopkins University· Source

• Completed

  Nebulized Bacteriophage Therapy in Cystic Fibrosis Patients With Chronic Pseudomonas Aeruginosa Pulmonary Infection

  NCT05010577· Phase 1/2· BiomX, Inc.· Source

• Completed

  Efficacy and Safety of Apitegromab in Patients With Later-Onset Spinal Muscular Atrophy Treated With Nusinersen or Risdiplam

  NCT05156320· Phase 3· Scholar Rock, Inc.· Source

• Completed

  Adjunctive GNX Treatment Compared With Placebo in Children and Adults With TSC-related Epilepsy

  NCT05323734· Phase 3· Marinus Pharmaceuticals· Source

• Terminated

  A Study of Soticlestat as an Add-on Therapy in Children and Adults With Dravet Syndrome or Lennox-Gastaut Syndrome

  NCT05163314· Phase 3· Takeda· Source

• Completed

  Evaluation of Long-term Safety and Efficacy of ELX/TEZ/IVA in Cystic Fibrosis (CF) Participants 2 Years and Older

  NCT05153317· Phase 3· Vertex Pharmaceuticals Incorporated· Source

• Completed

  A Study of Soticlestat as an Add-on Therapy in Children, Teenagers, and Adults With Lennox-Gastaut Syndrome

  NCT04938427· Phase 3· Takeda· Source

• Completed

  A Study of Soticlestat as an Add-on Therapy in Children and Young Adults With Dravet Syndrome

  NCT04940624· Phase 3· Takeda· Source

• Completed

  Pivotal-Safety and Therapeutic Measures of tDCS in Patients With Refractory Focal Epilepsy

  NCT04770337· Neuroelectrics Corporation· Source

• Completed

  Intervention for Sleep and Pain in Youth: A Randomized Controlled Trial

  NCT04936321· Seattle Children's Hospital· Source

• Terminated

  Testing the Combination of Two Immunotherapy Drugs (Magrolimab and Dinutuximab) in Patients With Relapsed or Refractory Neuroblastoma or Relapsed Osteosarcoma

  NCT04751383· Phase 1· National Cancer Institute (NCI)· Source

• Completed

  Teletherapy in Children Who Are Deaf and Hard of Hearing

  NCT04928209· University of California, San Francisco· Source

• Completed

  The PROMISE Pediatric Study 6 to 11 Years Old

  NCT04613128· Nicole Hamblett· Source

• Terminated

  Phase 3 Trial of Pamrevlumab or Placebo in Combination With Systemic Corticosteroids in Participants With Ambulatory DMD

  NCT04632940· Phase 3· Kyntra Bio· Source

• Terminated

  A Study to Evaluate Efficacy and Safety of Vatiquinone for Treating Mitochondrial Disease in Participants With Refractory Epilepsy

  NCT04378075· Phase 2/3· PTC Therapeutics· Source

• Terminated

  A Study of Lorcaserin as Adjunctive Treatment in Participants With Dravet Syndrome

  NCT04572243· Phase 3· Eisai Inc.· Source

• Terminated

  A Study to Evaluate Safety, Efficacy and Pharmacokinetics of Paricalcitol For Treatment of Secondary Hyperparathyroidism (SHPT) in Pediatric Participants With Stage 5 Chronic Kidney Disease (CKD)

  NCT04064827· Phase 3· AbbVie· Source

• Completed

  An Open-Label Study to Investigate the Safety of Single and Multiple Ascending Doses in Children and Adolescents With Dravet Syndrome

  NCT04442295· Phase 1/2· Stoke Therapeutics, Inc· Source

• Recruiting

  Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)

  NCT04278404· Duke University· Source

• Completed

  Evaluation of Long-term Safety and Efficacy of ELX/TEZ/IVA TC Combination Therapy in Participants With Cystic Fibrosis Who Are 6 Years of Age and Older

  NCT04183790· Phase 3· Vertex Pharmaceuticals Incorporated· Source

• Completed

  PRISM for Adolescents With Type 1 Diabetes

  NCT03847194· Seattle Children's Hospital· Source

• Completed

  A Prospective Study to Evaluate Biological and Clinical Effects of Significantly Corrected CFTR Function

  NCT04038047· Nicole Hamblett· Source

• Completed

  Study of the Bromodomain (BRD) and Extra-Terminal Domain (BET) Inhibitors BMS-986158 and BMS-986378 in Pediatric Cancer

  NCT03936465· Phase 1· Dana-Farber Cancer Institute· Source

• Completed

  Fimepinostat in Treating Brain Tumors in Children and Young Adults

  NCT03893487· Early phase 1· Sabine Mueller, MD, PhD· Source

• Completed

  Study Of Palbociclib Combined With Chemotherapy In Pediatric Patients With Recurrent/Refractory Solid Tumors

  NCT03709680· Phase 2· Pfizer· Source

• Completed

  Pevonedistat, Azacitidine, Fludarabine Phosphate, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome

  NCT03813147· Phase 1· National Cancer Institute (NCI)· Source

• Completed

  The PRISM Intervention: a Multi-site Randomized Controlled Trial for Adolescents and Young Adults With Advanced Cancer

  NCT03668223· Dana-Farber Cancer Institute· Source

• Completed

  EGFR806-specific CAR T Cell Locoregional Immunotherapy for EGFR-positive Recurrent or Refractory Pediatric CNS Tumors

  NCT03638167· Phase 1· Seattle Children's Hospital· Source

• Completed

  Clinical Benefit of Using Molecular Profiling to Determine an Individualized Treatment Plan for Patients With High Grade Glioma

  NCT03739372· University of California, San Francisco· Source

• Completed

  MIBG With Dinutuximab +/- Vorinostat

  NCT03332667· Phase 1· New Approaches to Neuroblastoma Therapy Consortium· Source

• Completed

  Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial)

  NCT03526250· Phase 2· National Cancer Institute (NCI)· Source

• Completed

  Long-term Safety With Vedolizumab Intravenous (IV) in Pediatric Participants With Ulcerative Colitis (UC) or Crohn's Disease (CD)

  NCT03196427· Phase 2· Takeda· Source

• Completed

  DAY101 In Gliomas and Other Tumors

  NCT03429803· Phase 1· Karen D. Wright, MD· Source

• Completed

  Pepinemab in Treating Younger Patients With Recurrent, Relapsed, or Refractory Solid Tumors

  NCT03320330· Phase 1/2· Children's Oncology Group· Source

• Completed

  Pevonedistat, Irinotecan, and Temozolomide in Treating Patients With Recurrent or Refractory Solid Tumors or Lymphoma

  NCT03323034· Phase 1· Children's Oncology Group· Source

• Completed

  Biospecimen Analysis in Determining Effects of Chemotherapy on Fertility in Osteosarcoma Survivors

  NCT03206450· Children's Oncology Group· Source

• Completed

  Web-Based Physical Activity Intervention in Improving Long Term Health in Children and Adolescents With Cancer

  NCT03223753· Phase 3· Children's Oncology Group· Source

• Completed

  Samotolisib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial)

  NCT03213678· Phase 2· National Cancer Institute (NCI)· Source

• Completed

  Phase II Study of Binimetinib in Children and Adults With NF1 Plexiform Neurofibromas

  NCT03231306· Phase 2· University of Alabama at Birmingham· Source

• Completed

  Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial)

  NCT03213665· Phase 2· National Cancer Institute (NCI)· Source

• Completed

  Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial)

  NCT03220035· Phase 2· National Cancer Institute (NCI)· Source

• Completed

  Adolescent Master Protocol for Participants 18 Years of Age or Older - Lite

  NCT03279185· Harvard School of Public Health (HSPH)· Source

Showing 50 of 102.

Conditions

Diseases this institution publishes on or runs trials for.

• Cystic fibrosis37 works · 16 trials
• Congenital heart disease34 works · 8 trials
• Childhood cancers23 works · 209 trials
• Acute lymphoblastic leukaemia19 works · 29 trials
• Down syndrome13 works · 9 trials
• Duchenne muscular dystrophy8 works · 8 trials
• Hydrocephalus8 works · 2 trials
• Dermatomyositis and polymyositis (myositis)4 works · 0 trials